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Abstract
Epithelial growth factor receptor (EGFR) directed tyrosine kinase inhibitor (TKI)
treatment is the standard approach in patients with advanced, EGFR-mutated
non-small cell lung cancer (NSCLC). Although benefit/risk ratio is favorable for
these TKI and side effects are manageable in the vast majority of patients, severe
and even life-threatening side effects have been reported. TKI-induced interstitial
lung disease (ILD) has been reported for single cases in modest severity, predom-
inantly in EGFR-TKI pretreated patients. Here, we report a case of successful sta-
bilization of a life-threatening ILD in a de novo T790M mutated NSCLC during
first-line treatment with osimertinib. As osimertinib will be used more often in
many EGFR-positive NSCLC patients in the future, this potentially life-
threatening side effect should receive special attention, especially in first-line
treatment.
Introduction
Interstitial lung disease (ILD) is a known side effect of
epithelial growth factor receptor (EGFR) directed treat-
ment with tyrosine kinase inhibitors (TKI).1-6 In rare
cases, ILD may be a serious and potentially life-
threatening event.7-9 With increasing numbers of EGFR-
TKI treated patients, this serious side effect becomes
increasingly relevant. Incidence and severity of TKI
induced ILD varies between different TKIs and between
initial and re-exposure to an EGFR- directed treatment8
or after preceding PD-L1 directed treatment.10-13 In con-
trast to acquired T790M mutation, data on side effects
for patients with de novo/primary T790M mutated non-
small cell lung cancer (NSCLC) is limited. We present a
case of acute pneumonitis with resultant respiratory
failure and need for mechanical ventilation after first
line-treatment with the TKI oisimertinib in a primary
T790M mutated NSCLC patient.
Case report
A 79 year-old non-smoker, with no pre-existing pulmonary
disease, was diagnosed with NSCLC of the left upper lung
complicated by adrenal and bone metastases (Fig 1a, white
arrow). Molecular genetic analysis at first diagnosis rev-
ealed both an EGFR mutation p.L858R in exon 21 and a p.
T790M mutation in exon 20 (but no other molecular alter-
ation relevant for treatment). First-line treatment with
osimertinib was initiated using a standard dose of 80 mg
per day (as an off label application at that time). Initial
lung function showed a normal diffusion capacity and a
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mild pulmonary restriction with a vital capacity (VC) of
75% of predicted value.
Osimertinib led to a partial remission of NSCLC after
three months without any obvious clinical or radiological
side-effects (Fig 1b, white arrow). However, one week later,
the patient presented to another hospital with sudden onset
of mild dyspnoea. CT scan excluded pulmonary embolism,
but showed new, predominantly subpleural, and
bipulmonary opacities (Fig 1c, black arrows). The patient
received no further investigation or treatment and
osimertinib treatment was continued. Dyspnea worsened
over the subsequent three weeks, and the patient re-
presented to the same hospital with severe hypoxemia and
progressive pulmonary infiltrations (Fig 1d). He rapidly
developed acute respiratory failure requiring mechanical
ventilation, and was subsequently transferred to our hospital.
Figure 1 High-resolution com-
puted tomography (HRCT) scan
of the thorax showing subse-
quent pulmonary changes. (a)
Before osimertinib treatment; (b)
after four months of osimertinib
treatment, no clinical symptoms;
(c) ongoing treatment with
osimertinib, onset of dyspnea; (d)
osimertinib treatment was
stopped due to severe hypoxia;
(e) no osimertinib, mechanical
ventilation, high dose steroid
treatment; (f) ongoing mechani-
cal ventilation due to severe hyp-
oxia, steroid treatment; (g)
ongoing steroid treatment, with
a slow improvement; and (h) no
tumor treatment, tumor progres-
sion. White arrows mark the pri-
mary tumor, black arrows mark
pulmonary infiltrates.
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Tests showed a slight elevation of infection parameters.
Serology, blood cultures and bronchoalveolar lavage failed
to reveal any causal pathogen. Transbronchial biopsy for
histopathological evaluation could not be performed due to
gross persisting hypoxemia under mechanical ventilation
with an inspiratory oxygen concentration requirement of
up to 90%. Other than osimertinib there had been no
change in medication in the preceding four months.
We considered osimertinib-induced acute pneumonitis
to be the first differential diagnosis in the absence of any
other obvious or potential alternative, and osimertinib
treatment was immediately stopped. High dose predniso-
lone with 500 mg over three days, followed by 100 mg per
day for 14 days was given (Fig 1e).14 However, impaired
oxygenation persisted over the next two weeks in parallel
with persisting pulmonary infiltrates (Fig 1f), and the
patient required tracheostomy. Steroid treatment was con-
tinued leading to stabilization and subsequent slow
improvement in the lung impairment (Fig 1g), resulting in
successful weaning and decannulation 47 days after intuba-
tion. Steroid treatment was tapered slowly, and stopped
after a further eight weeks. The patient’s condition contin-
ued to improve, although he continued to have severe
restrictive pulmonary impairment (VC 37% of the
predicted value) and critical care polyneuropathy.
Follow-up at three and five months (Fig 1h) after stop-
ping osimertinib showed accelerating tumor growth,
although the patient’s condition further improved to an
ECOG performance status of 1–2. Following three months
(six cycles) of second-line treatment with carboplatin and
gemcitabine the disease stabilized. Subsequent relapse
treatment with pemetrexed was initiated which has stabi-
lized tumor activity until now, over two years after first
diagnosis.
Discussion
Although TKI treatment leads to benefits in terms of
progression-free and overall survival in EGFR- mutated
NSCLC patients,15–17 it is necessary to be aware of poten-
tial side effects. Based on previous reports and our experi-
ence, we suggest routine clinical and lung function
evaluation if respiratory symptoms develop in such
patients. In case of a severe TKI-associated ILD,
osimertinib treatment should be stopped immediately. In
our patient, transient mechanical ventilation and high dose
steroid treatment achieved stabilization in this life-
threatening situation.
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